NEW YORK–(BUSINESS WIRE)–#Action–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) on behalf of Sema4 stockholders. Our investigation concerns whether Sema4 has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On July 22, 2021, CM Life Sciences, Inc., a special purpose acquisition company, completed its business combination with Mount Sinai Genomics, Inc., and the combined public entity was renamed Sema4.
Less than a year later, on June 14, 2022, Sema4 announced that its Chief Financial Officer had departed.
Then, on August 15, 2022, after the market closed, Sema4 announced changes to its research and development team, including that its founder was stepping down from the organization and leaving his role as President and chief R&D Officer. The Company also disclosed that it was eliminating approximately 13% of its workforce as part of a series of restructuring and corporate realignments. Additionally, Sema4 lowered its 2022 revenue guidance to $245 million to $255 million from its prior guidance of $305 million to $315 million.
On this news, Sema4’s stock fell $0.80, or 33.3%, to close at $1.60 per share on August 16, thereby injuring investors.
If you purchased or otherwise acquired Sema4 shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.